Table 2.

Efficacy results in full analysis set.

	QL1209 n/N (%, 90%)	Reference pertuzumab n/N (%, 90%)	Relative risk
Assessed by IRC
tpCR	109/255 (42.75; 37.65 to 47.84)	117/259 (45.17; 40.09 to 50.26)	0.95 (0.80 to 1.11)
tpCR according to clinical stage
Early stage	69/159 (43.40; 36.93 to 49.86)	80/165 (48.48; 42.09 to 54.88)
Locally advanced	40/96 (41.67; 33.39 to 49.94)	37/94 (39.36; 31.07 to 47.65)
bpCR	128/256 (50.00; 44.86 to 55.14)	134/259 (51.74; 46.63 to 56.84)
Assessed by INV
tpCR	109/257 (42.41; 37.34 to 47.48)	120/259 (46.33; 41.24 to 51.43)	0.92 (0.78 to 1.08)
bpCR	125/257 (48.64; 43.51 to 53.77)	133/259 (51.35; 46.24 to 56.46)
ORR	212/257 (82.49; 78.59 to 86.39)	212/259 (81.85; 77.91 to 85.79)

Data are n (%; 90% CI), IRC independent review committee, INV investigator, tpCR total pathological complete response, bpCR breast pathological complete response, ORR objective response rate.